THIOPURINE METHYLTRANSFERASE ACTIVITY IN AMERICAN WHITE SUBJECTS AND BLACK SUBJECTS

被引:217
作者
MCLEOD, HL
LIN, JS
SCOTT, EP
PUI, CH
EVANS, WE
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN USA
[3] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN USA
[4] UNIV TENNESSEE, COLL PHARM, DEPT PEDIAT, CTR PEDIAT PHARMACOKINET & THERAPEUT, MEMPHIS, TN USA
[5] UNIV TENNESSEE, COLL PHARM, DEPT CLIN PHARM, MEMPHIS, TN USA
[6] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, CTR PEDIAT & CLIN PHARM, MEMPHIS, TN USA
[7] UNIV TENNESSEE, COLL MED, DEPT CLIN PHARM, MEMPHIS, TN USA
关键词
D O I
10.1038/clpt.1994.4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Thiopurine methyltransferase (TPMT) is a cytoplasmic enzyme that preferentially catalyzes the S-methylation of aromatic and heterocyclic sulthydryl compounds, including 6-mercaptopurine. TPMT exhibits genetic polymorphism in white populations, with 89% of individuals having high TPMT activity, 11% having intermediate activity, and one in 300 having extremely low or absent activity. TPMT activity is inversely correlated with formation of active 6-mercaptopurine metabolites (thioguanine nucleotides), thereby influencing 6-mercaptopurine toxicity and efficacy. Methods: To investigate ethnic and gender differences in TPMT, we measured erythrocyte TPMT activity in 209 white healthy subjects and 196 black healthy subjects (202 women and 203 men). Results: The black population had lower TPMT activity than the white population (median, 14.4 versus 16.8 units/ml packed erythrocytes; p < 0.001). Maximum likelihood estimation of TPMT activity distribution identified 91.9% and 93.9% with high activity and 7.7% and 6.1% with intermediate activity in the white and black groups, respectively. Conclusions: These data indicate that TPMT activity is similarly polymorphic in American black subjects and white subjects, although median TPMT activity is approximately 17% lower in black subjects.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 33 条
[1]   GENETIC-BASIS FOR A LOWER PREVALENCE OF DEFICIENT CYP2D6 OXIDATIVE DRUG-METABOLISM PHENOTYPES IN BLACK-AMERICANS [J].
EVANS, WE ;
RELLING, MV ;
RAHMAN, A ;
MCLEOD, HL ;
SCOTT, EP ;
LIN, JS .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (05) :2150-2154
[2]   ALTERED MERCAPTOPURINE METABOLISM, TOXIC EFFECTS, AND DOSAGE REQUIREMENT IN A THIOPURINE METHYLTRANSFERASE-DEFICIENT CHILD WITH ACUTE LYMPHOCYTIC-LEUKEMIA [J].
EVANS, WE ;
HORNER, M ;
CHU, YQ ;
KALWINSKY, D ;
ROBERTS, WM .
JOURNAL OF PEDIATRICS, 1991, 119 (06) :985-989
[3]  
Everitt B, 2013, FINITE MIXTURE DISTR
[4]  
GAYNON PS, 1988, LANCET, V2, P921
[5]  
HONCHEL R, 1993, MOL PHARMACOL, V43, P878
[6]   A DISTRIBUTION-FREE KAPPA-SAMPLE TEST AGAINST ORDERED ALTERNATIVES [J].
JONCKHEERE, AR .
BIOMETRIKA, 1954, 41 (1-2) :133-145
[7]  
JONES DC, 1993, CLIN PHARMACOL THER, V53, P348
[8]   VARIATION BY RACE IN PRESENTING CLINICAL AND BIOLOGIC FEATURES OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - IMPLICATIONS FOR TREATMENT OUTCOME [J].
KALWINSKY, DK ;
RIVERA, G ;
DAHL, GV ;
ROBERSON, P ;
GEORGE, S ;
MURPHY, SB ;
SIMONE, JV .
LEUKEMIA RESEARCH, 1985, 9 (06) :817-823
[9]   INTERETHNIC DIFFERENCE IN THIOPURINE METHYLTRANSFERASE ACTIVITY [J].
KLEMETSDAL, B ;
TOLLEFSEN, E ;
LOENNECHEN, T ;
JOHNSEN, K ;
UTSI, E ;
GISHOLT, K ;
WIST, E ;
AARBAKKE, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :24-31
[10]  
KRUSKAL WILLIAM H., 1952, JOUR AMER STATIST ASSOC, V47, P583, DOI 10.2307/2280779